Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Company profile
Ticker
ALLO
Exchange
Website
CEO
David D. Chang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
SEC CIK
ALLO stock data
News
Allogene Therapeutics Announces Oral Presentation Of Pre-clinical Data Highlighting Improved Anti-Tumor Activity Of Donor-Derived Allogeneic CAR T Cells At American Society Of Gene And Cell Therapy Annual Meeting
19 May 22
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 May 22
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
10 May 22
Raymond James Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $13
5 May 22
Allogene Therapeutics Q1 EPS $(0.56) Beats $(0.58) Estimate
4 May 22
Press releases
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
19 May 22
Allogene Therapeutics Reports First Quarter 2022 Financial Results
4 May 22
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
28 Apr 22
Thinking about buying stock in Mattel, Zentalis Pharmaceuticals, Acutus Medical, Allogene Therapeutics, or NeoGenomics?
27 Apr 22
Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
27 Apr 22
Analyst ratings and price targets
Current price
Average target
$12.50
Low target
$12.00
High target
$13.00
Raymond James
Maintains
$13.00
Goldman Sachs
Maintains
$12.00
Investment data
Securities sold
Number of investors
Calendar
4 May 22
24 May 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.81M | 94.81M | 94.81M | 94.81M | 94.81M | 94.81M |
Cash burn (monthly) | 29.6M | 12.63M | 26.66M | 25.22M | 22.75M | 16.98M |
Cash used (since last report) | 52.57M | 22.42M | 47.36M | 44.79M | 40.4M | 30.15M |
Cash remaining | 42.23M | 72.38M | 47.45M | 50.02M | 54.41M | 64.65M |
Runway (months of cash) | 1.4 | 5.7 | 1.8 | 2.0 | 2.4 | 3.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 May 22 | Amado Rafael | Common Stock | Sell | Dispose S | No | No | 7.3993 | 11,500 | 85.09K | 546,257 |
31 Mar 22 | Equity Holdings 2 B.V. PF | Common Stock | Other | Dispose J | No | No | 0 | 22,032,040 | 0 | 0 |
23 Mar 22 | Veer Bhavnagri | Common Stock | Grant | Acquire A | No | No | 0 | 175,438 | 0 | 589,279 |
23 Mar 22 | Veer Bhavnagri | Stock Option Common Stock | Grant | Acquire A | No | No | 9.69 | 272,435 | 2.64M | 272,435 |
23 Mar 22 | Schmidt Eric Thomas | Common Stock | Grant | Acquire A | No | No | 0 | 237,358 | 0 | 337,904 |
23 Mar 22 | Schmidt Eric Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 9.69 | 368,589 | 3.57M | 368,589 |
23 Mar 22 | Moore Alison | Stock Option Common Stock | Grant | Acquire A | No | No | 9.69 | 737,179 | 7.14M | 737,179 |
Institutional ownership, Q1 2022
86.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 180 |
Opened positions | 32 |
Closed positions | 32 |
Increased positions | 71 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 1.16B |
Total shares | 124.56M |
Total puts | 79.6K |
Total calls | 119.3K |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 22.03M | $200.71M |
TPG GP A | 18.72M | $170.51M |
STT State Street | 7.88M | $71.77M |
BLK Blackrock | 7.09M | $64.56M |
Seaview Trust | 7.04M | $105.05M |
Vanguard | 6.75M | $61.53M |
Primecap Management | 4.91M | $44.7M |
Belldegrun Arie | 4.71M | $0 |
TROW T. Rowe Price | 4.27M | $38.87M |
JPM JPMorgan Chase & Co. | 3.56M | $32.41M |
Financial report summary
?Competition
Bristol-Myers Squibb • AMGEN • Celgene • Immunogen • Regeneron Pharmaceuticals • Gilead Sciences • Astrazeneca • Sangamo Therapeutics • Seagen • Alaunos TherapeuticsRisks
- We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*
- Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.*
- Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.
- The COVID-19 global pandemic has and is adversely impacting our business, including our preclinical studies and clinical trials.*
- We are heavily reliant on our partners for access to TALEN gene editing technology for the manufacturing and development of our product candidates.
- Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.
- Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.
- Our product candidates may cause undesirable side effects or have other properties that have halted and could in the future halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*
- Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.
- Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- We may not be able to submit INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.
- We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.
- Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.
- If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*
- The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.
- Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.
- We may fail to successfully manufacture our product candidates, operate our own manufacturing facility, or obtain regulatory approval to utilize or commercialize from our manufacturing facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.
- As a company, we have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.
- A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.
- We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
- We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*
- We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*
- We may form or seek additional strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
- We may not realize the benefits of acquired assets or other strategic transactions.*
- We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*
- If our security measures, or those of our CROs, CMOs, collaborators, contractors, consultants or other third parties upon whom we rely, are compromised now, or in the future, or the security, confidentiality, integrity or availability of our information technology, software, services, networks, communications or data is compromised, limited or fails, we could experience a material adverse impact including, without limitation, a material interruption to our operations, including our
- clinical trials, harm to our reputation, significant fines, penalties and liability, or a breach or triggering of data protection laws, privacy policies and data protection obligations.
- Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
- Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.*
- Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.
- We are subject to stringent and changing privacy laws, regulations and standards as well as policies, contracts and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to enforcement or litigation (that could result in fines or penalties), a disruption of clinical trials or commercialization of products, reputational harm, or other adverse business effects.*
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
- We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
- We rely on third parties to manufacture and store our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*
- We rely on T cells from healthy donors to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted.
- Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.*
- If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.
- The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
- The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.*
- The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.
- We may be unable to obtain regulatory approval for ALLO-647 in a timely manner or at all, which could delay any approval or commercialization of our allogeneic T cell product candidates.
- Regenerative Medicine Advanced Therapy designation and Fast Track designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.*
- We plan to seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.
- Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
- We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
- Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.
- Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.
- The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.
- We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
- If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.
- Confidentiality agreements with employees, Allogene Overland and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
- Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.
- We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
- We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
- The lives of our patents may not be sufficient to effectively protect our products and business.
- We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.
- Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.
- Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
- We may not be able to protect our intellectual property rights throughout the world.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
- Unstable market, economic and geo-political conditions may have serious adverse consequences on our business, financial condition and stock price.*
- Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
- If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
Management Discussion
- Collaboration revenue was less than $0.1 million and $38.3 million for the three months ended March 31, 2022 and 2021, respectively. The decrease of $38.3 million was due to the revenue recognized related to the license of intellectual property and delivery of the know-how performance obligation, which was delivered in the first quarter of 2021, under the License Agreement entered into with Allogene Overland in December 2020.
- Research and development expenses were $60.2 million and $55.2 million for the three months ended March 31, 2022 and 2021, respectively. The increase of $5.0 million was driven primarily by an increase in personnel related costs of $6.5 million, of which $3.2 million was stock-based compensation expense, and an increase in facilities costs and depreciation expense of $4.1 million, offset by a $6.7 million decrease in external costs relating to the advancement of our product candidates due to the timing of development activities and manufacturing runs.
- General and administrative expenses were $19.9 million and $16.4 million for the three months ended March 31, 2022 and 2021, respectively. The increase of $3.5 million was primarily due to an increase in personnel related costs of $3.8 million, of which $2.4 million was stock-based compensation expense.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accidental, alleviate, alteration, Antion, banning, bound, brain, built, caption, credential, deploying, disorder, draft, encryption, ERP, ESG, Extortion, flood, framework, FTD, geopolitical, Gilead, HQ, hypokinetic, Janssen, Johnson, LBCL, led, miCAR, military, miRNA, misconduct, modification, morale, multiplex, necessitate, network, neurocognitive, offline, online, outbreak, Parkinson, passed, PIPL, posture, PRC, retaliatory, Russia, silencing, stuffing, tool, tumor, UK, Ukraine, underwater, unlawful, unwilling, Utah, virulent
Removed:
accurate, acted, active, Aid, American, analogy, applied, applying, ASC, behave, Biden, branded, compromise, consistently, CPPA, cyber, cyberattack, declared, demonstration, discontinuing, disruptive, domestic, dubbed, espionage, expedite, experiencing, extraterritorially, finalize, fiscal, gap, Goldman, Hematology, hostile, industrial, informally, Institute, interfere, intermediate, iv, legislation, marketable, methodology, minimum, Morgan, nonrefundable, optimize, outpatient, percent, pertaining, prescription, promise, rebate, reconsider, reexamining, reflecting, reflective, regime, registered, responsibility, reverse, robust, ruling, Society, subjected, supplying, surrogate, Topic, transferred, treated, unclear, undergo, unmet, usability, utilization, waiver, wire, wrongful
Financial reports
Current reports
8-K
Allogene Therapeutics Reports First Quarter 2022 Financial Results
4 May 22
8-K
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021
23 Feb 22
8-K
Entry into a Material Definitive Agreement
15 Dec 21
8-K
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
4 Nov 21
8-K
Other Events
7 Oct 21
8-K
Allogene Therapeutics Reports Second Quarter 2021 Financial Results
4 Aug 21
8-K
Departure of Directors or Certain Officers
2 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 21
8-K
Departure of Directors or Certain Officers
20 May 21
8-K
Other Events
19 May 21
Registration and prospectus
SC TO-C
Information about tender offer
14 Apr 22
S-8
Registration of securities for employees
23 Feb 22
S-8
Registration of securities for employees
25 Feb 21
424B5
Prospectus supplement for primary offering
3 Jun 20
424B5
Prospectus supplement for primary offering
1 Jun 20
S-8
Registration of securities for employees
26 Feb 20
S-3ASR
Automatic shelf registration
5 Nov 19
S-8
Registration of securities for employees
8 Mar 19
S-8
Registration of securities for employees
24 Oct 18
POS EX
Additional exhibits for listing
15 Oct 18
Proxies
Other
CT ORDER
Confidential treatment order
25 Oct 21
EFFECT
Notice of effectiveness
11 Oct 18
CT ORDER
Confidential treatment order
10 Oct 18
CERT
Certification of approval for exchange listing
10 Oct 18
CORRESP
Correspondence with SEC
3 Oct 18
CORRESP
Correspondence with SEC
3 Oct 18
CORRESP
Correspondence with SEC
1 Oct 18
CORRESP
Correspondence with SEC
25 Sep 18
UPLOAD
Letter from SEC
25 Sep 18
CORRESP
Correspondence with SEC
13 Sep 18
Ownership
4
Allogene Therapeutics / Rafael Amado ownership change
19 May 22
SC 13D/A
Allogene Therapeutics / PFIZER ownership change
7 Apr 22
4
Allogene Therapeutics / Equity Holdings 2 B.V. PF ownership change
4 Apr 22
4/A
Allogene Therapeutics / Arie Belldegrun ownership change
1 Apr 22
4
Allogene Therapeutics / Arie Belldegrun ownership change
31 Mar 22
4
Allogene Therapeutics / Rafael Amado ownership change
25 Mar 22
4
Allogene Therapeutics / David D Chang ownership change
25 Mar 22
4
Allogene Therapeutics / ALISON MOORE ownership change
25 Mar 22
4
Allogene Therapeutics / Arie Belldegrun ownership change
25 Mar 22
4
Allogene Therapeutics / ERIC THOMAS SCHMIDT ownership change
25 Mar 22
Patents
Utility
Modified caspase-9 polypeptides and methods of use thereof
10 May 22
Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides.
Utility
Inhibitory Chimeric Antigen Receptors
3 Feb 22
Inventors: ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Utility
Chimeric Antigen Receptors with Enhanced Signaling and Activities and Uses Thereof
27 Jan 22
Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety.
Utility
Bcma Car-t Cells with Enhanced Activities
26 Aug 21
Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR).
Utility
Inhibitory chimeric antigen receptors
27 Jul 21
The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
Transcripts
2022 Q1
Earnings call transcript
5 May 22
2021 Q4
Earnings call transcript
24 Feb 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
28 Feb 21
2020 Q3
Earnings call transcript
4 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
9 May 20
2019 Q4
Earnings call transcript
27 Feb 20
Reddit threads
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Daily Discussion Thread - February 23rd, 2022
23 Feb 22
Daily Discussion Thread - February 22nd, 2022
22 Feb 22
Daily Discussion Thread - February 21st, 2022
21 Feb 22
🔮WallStreetBets Predictions Tournament for February 2022🔮
6 Feb 22
A Rush For The Exits
20 Jan 22
What are your predictions for top performing sectors in 2022?
5 Jan 22
Cowen Top 2022 Ideas
13 Dec 21